A carregar...
Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Introduction: A proof-of-concept study was designed to evaluate the antiviral efficacy, safety and tolerability of a two-drug regimen with dolutegravir 50 mg once daily (QD) plus lamivudine 300 mg once daily as initial highly active antiretroviral therapy (HAART) among antiretroviral (ARV)-naive pat...
Na minha lista:
| Publicado no: | J Int AIDS Soc |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5515053/ https://ncbi.nlm.nih.gov/pubmed/28537061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.20.01.21678 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|